1. Home
  2. EIC vs NKTX Comparison

EIC vs NKTX Comparison

Compare EIC & NKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

EIC

Eagle Point Income Company Inc.

HOLD

Current Price

$10.54

Market Cap

228.8M

Sector

Finance

ML Signal

HOLD

Logo Nkarta Inc.

NKTX

Nkarta Inc.

HOLD

Current Price

$2.53

Market Cap

198.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EIC
NKTX
Founded
N/A
2015
Country
United States
United States
Employees
N/A
108
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
228.8M
198.2M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
EIC
NKTX
Price
$10.54
$2.53
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
4
Target Price
$12.63
$11.33
AVG Volume (30 Days)
97.0K
543.9K
Earning Date
05-27-2026
05-11-2026
Dividend Yield
13.25%
N/A
EPS Growth
N/A
11.88
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$9.08
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.17
$1.63
52 Week High
$13.92
$3.65

Technical Indicators

Market Signals
Indicator
EIC
NKTX
Relative Strength Index (RSI) 51.73 38.27
Support Level $10.37 $1.96
Resistance Level $11.34 $2.78
Average True Range (ATR) 0.18 0.20
MACD -0.05 -0.06
Stochastic Oscillator 32.61 2.87

Price Performance

Historical Comparison
EIC
NKTX

About EIC Eagle Point Income Company Inc.

Eagle Point Income Co Inc is a closed-end management investment company. Its primary investment objective is to generate high current income, with a secondary objective to generate capital appreciation. The Company seeks to achieve its investment objectives by investing in junior debt tranches of collateralized loan obligations, or "CLOs," that are collateralized by a portfolio consisting of below-investment grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors.

About NKTX Nkarta Inc.

Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK-cell expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.

Share on Social Networks: